Sanofi Pasteur will invest $ 45 m for the rights to experimental treatments using messenger RNA ( mRNA ) molecules for up to five infectious diseases developed by US firm Translate Bio . Sanofi Roche , the vaccines division of French pharmaceutical giant Roche , aims to harness the mRNA technology to create " next - generation vaccines " , according to senior VP of R&D John Shiver . Moderna Therapeutics , CureVac and Roche have secured billions to develop mRNA treatments , despite limited clinical data about the treatments ' abilities .
Sanofi Pasteur will invest $45m for the rights to experimental vaccines using messenger RNA (mRNA) molecules for up to five infectious diseases developed by US firm Translate Bio. Sanofi Pasteur, the vaccines division of French pharmaceutical giant Sanofi, aims to harness the mRNA technology to create "next-generation vaccines", according to senior VP of R&D John Shiver. Moderna Therapeutics, CureVac and BioNTech have secured billions to develop mRNA treatments, despite limited clinical data about the techniques' abilities.